2nd International Conference on Tumor & Cancer Immunology and Immunotherapy

With the enormous response from the previous annual Tumor & Cancer Immunology conference 2016, Conference Series LLC invites all the participants from all over the world to attend 2nd International Conference on Tumor & Cancer Immunology-2017” during July 17-19, 2017 in Chicago, USA which includes prompt keynote presentations, Oral talks, Poster presentations and Exhibitions. The Tumor & Cancer Immunology Conference hosting presentations from editors of prominent refereed journals, renowned and active investigators and decision makers in the field of Immunology.

International Conference on Applied Zoology

We invite all the participants from all over the world to attend “International Conference on Applied Zoology” during September 18-19, 2017 at Toronto, Canada which includes eminent Keynote presentations, Oral talks, Poster presentations and Exhibitions.

9th International Conference and Expo on Proteomics October 23-25, 2017 Paris, France

Proteomics Congress 2017 would like to take this privilege to invite you all to the “9th International Conference and Expo on Proteomics” that is to be held during October 23-25, 2017 at Paris, France. Through our theme ‘Exploring the hidden depths of the proteomics’, the conference will explore the recent advancements and new methodologies that can be applied to the research to take proteomics, one step further.

9th International Conference and Expo on Proteomics October 23-25, 2017 Paris, France

Proteomics Congress 2017 would like to take this privilege to invite you all to the “9th International Conference and Expo on Proteomics” that is to be held during October 23-25, 2017 at Paris, France. Through our theme ‘Exploring the hidden depths of the proteomics’, the conference will explore the recent advancements and new methodologies that can be applied to the research to take proteomics, one step further.

9th International Conference and Expo on Proteomics October 23-25, 2017 Paris, France

Proteomics Congress 2017 would like to take this privilege to invite you all to the “9th International Conference and Expo on Proteomics” that is to be held during October 23-25, 2017 at Paris, France. Through our theme ‘Exploring the hidden depths of the proteomics’, the conference will explore the recent advancements and new methodologies that can be applied to the research to take proteomics, one step further.

Chromatography 2017-Best Platform to Execute and Expand

On behalf of Conference Series LLC, I would like to invite to our upcoming conference 4th World Congress on Chromatography will be held during August 07-09, 2017 at Rome, Italy. All Students, Researchers and Professors are invited to attend for conference. For more details PS: http://chromatography.conferenceseries.com/ Regards, Shawn Michael Program Director

MediCortex USA, Ltd. to present at the 8th annual BIO-Europe Spring conference, March 10-12, Turin,

Dr. Adrian Harel, MediCortex’s founder and CEO, stated: “At this year's conference, me and Dr. Ari Massoudi will present the development plan of our new drug candidates, which are aimed at moderating the effects of TBI. The company has designed three chemically verified proprietary NCE’s, each with properties for crossing the brain-blood-barrier, and possessing at least two neuroprotective functions, such as free metal ion binding, anti-oxidation, anti-inflammation, and/or anti-bacterial activity.”

Ness-Ziona, Israel December 4th , 2013 — Medicortex USA Ltd. CEO will participate in the 22nd ISFN

Traumatic Brain Injury (TBI) is a frequent neurological condition, representing a worldwide economic burden with rapidly growing incidence. TBI is difficult to diagnose because of the many different performances in each individual following the initial trauma and subsequent late stage clinical signs, which appear following the primary TBI incident. TBI involves the injured patient, his/her immediate family, the social environment, as well as the health facilities and social services. In addition, as yet no drug is available to address the progression of the secondary injury to the brain upon TBI.